Choline Nutritional Status Of Children With Cystic Fibrosis X-Sectional Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Cystic fibrosis (CF) is the most common lethal, inherited disorder among Caucasians. Choline is an essential vitamin and as a methyl donor is critically needed to support the normal metabolism. Our previous studies have demonstrated that children with CF have depleted levels of choline. The purpose of this study is to gather data on the status of choline and related metabolites in children with Cystic Fibrosis by age and gender. The hypothesis for this study is that in children with CF, deficiency of choline and related metabolites will increase with increasing age.
| Condition |
|---|
|
Cystic Fibrosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
| Official Title: | Choline Nutritional Status Of Children With Cystic Fibrosis X-Sectional Study |
- The change in plasma choline and its metabolites with increasing age in children with CF compared to a healthy reference group without CF [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- The relationship between choline and acetylcholine, and markers of oxidative stress, inflammation and disturbed methyl metabolism [ Time Frame: 12 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 140 |
| Study Start Date: | October 2007 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
Children with proven CF and known genotype, age 0-17 yr
|
Detailed Description:
The objective of this clinical project is to determine the status of choline and related metabolites in a large group of children with Cystic Fibrosis (CF). Based on the results it will be possible to determine which children are deficient or at risk for choline deficiency, and might benefit most from supplementation to sustain improvement in the plasma choline, and its metabolites. This will be a cross-sectional study that will, over a 6 month period, look to enroll as many patients as possible from 140 children with CF who are seen regularly at the CF Clinic at B.C.'s Children's Hospital. The study will involve the collection of blood and urine at the time of a scheduled appointment. All procedures for enrollment, collection of chart data and blood samples will follow procedures used in our previous studies. Body weight and height will be measured and routine blood work including liver enzymes, hematology, serum zinc, selenium and vitamins A and E will be completed as part of the clinic appointment. CF genotype, gender, birth date, hematology, clinical chemistry, anthropometric and nutritional measures, liver ultrasound, biopsy reports where available, pancreatic function (elastase, chymotrypsin/secretin-CCK) and all medications including mineral, vitamin and nutritional and enzyme supplements will be recorded from chart data. Blood samples will be used for analyses of choline and its metabolites and various biomarkers in redox pathways. A urine sample will be collected and used to assay excretion of related metabolites. Creatine will be analyzed to avoid the need for quantitative 24 hour urine collection.
Eligibility| Ages Eligible for Study: | up to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Children with proven CF and known genotype, age 0-17 yr who are outpatients of the CF Clinic at the British Columbia (B.C.) Children's Hospital
Inclusion Criteria:
- children with proven CF and known genotype.
- age 0-17 yr.
- outpatients of the CF Clinic at the British Columbia (B.C.) Children's Hospital.
- Children without CF or any other known disease.
Exclusion Criteria:
- children with CF receiving parenteral nutrition during the previous week.
- children who are hospitalized.
- children with any health problems other than CF that might in the opinion of the investigators influence dietary choices, growth, choline or methyl metabolites.
Contacts and Locations| Contact: Sheila M. Innis, Dr. | 604-875-2431 | sinnis@interchange.ubc.ca |
| Canada, British Columbia | |
| Child & Family Research Institute, CF Clinic, BC Children's Hospital | Recruiting |
| Vancouver, British Columbia, Canada | |
| Contact: Sheila M. Innis, Dr. 604-875-2431 sinnis@interchange.ubc.ca | |
| Principal Investigator: | Sheila M. Innis, Dr. | University of British Columbia |
| Study Director: | A. George F. Davidson, MD | University of British Columbia |
More Information
No publications provided by University of British Columbia
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University of British Columbia |
| ClinicalTrials.gov Identifier: | NCT01150136 History of Changes |
| Other Study ID Numbers: | H07-01140 |
| Study First Received: | April 26, 2010 |
| Last Updated: | December 20, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by University of British Columbia:
|
choline cystic fibrosis methyl metabolism oxidative stress |
Additional relevant MeSH terms:
|
Cystic Fibrosis Fibrosis Pancreatic Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Pathologic Processes Choline |
Lipotropic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Gastrointestinal Agents Therapeutic Uses Lipid Regulating Agents Nootropic Agents Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 21, 2013